|Table of Contents|

Progress of childhood systemic Epstein-Barr virus positive T-cell lymphoproliferative disease

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 10
Page:
1948-1951
Research Field:
Publishing date:

Info

Title:
Progress of childhood systemic Epstein-Barr virus positive T-cell lymphoproliferative disease
Author(s):
XU Haisheng; MIAO Hongjun
Children's Hospital of Nanjing Medical University,Jiangsu Nanjing 210008,China.
Keywords:
Epstein-Barr virus; lymphoproliferative disease; lymphoma
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.10.035
Abstract:
In the latest classification of lymphoma by the World Health Organization in 2016,childhood systemic Epstein-Barr virus positive T-cell lymphoproliferative disease (CSEBV+T-LPD) was renamed as "systemic EBV+T-cell lymphoma of childhood" to emphasize its explosive clinical process.The disease lacks specific clinical features and the diagnosis requires comprehensive analysis of clinical manifestations,pathological morphology,immunohistochemical testing,EBV-EBER in situ hybridization and TCR gene testing.EBV plays an important role in promoting the occurrence of lymphoma,but its exact mechanism is still unclear,and more in-depth research is needed to provide a basis for accurate diagnosis and reliable treatment.At present,there is no standard treatment plan or consensus for the systemic EBV-positive T-cell lymphoid tissue proliferative disease in children.The overall prognosis of the disease is poor and the mortality rate is high.Allogeneic hematopoietic stem cell transplantation is currently an effective treatment for children with CSEBV+T-LPD.Gene hematopoietic stem cell transplantation can effectively eliminate EBV-infected cells and rebuild normal immunity to EBV.

References:

［1］ COHEN JI,KIMURA H,NAKAMURA S,et al.Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts:a status report and summary of an international meeting,8-9 September 2008［J］.Ann Oncol,2009,20(9):1472-1482.
［2］ SWERDLOW SH,CAMPO E,PILERI SA,et al.The 2016 revision of the World Health Organization classification neoplasms ［J］.Blood,2016,127(20):2375-2390.
［3］ SHAFIEE A,SHAMSI S,KOHANDEL GARGARI O,et al.EBV associated T- and NK-cell lymphoproliferative diseases:A comprehensive overview of clinical manifestations and novel therapeutic insights［J］.Rev Med Virol,2022,32(4):e2328.
［4］DOJCINOV SD,QUINTANILLA-MARTINEZ L.How I diagnose EBV-positive B- and T-cell lymphoproliferative disorders［J］.Am J Clin Pathol,2022,10:aqac105.
［5］ HUE SS,OON ML,WANG S,et al.Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases:an update and diagnostic approach［J］.Pathology,2020,52(1):111-127.
［6］XIAO SY.Comparison of systemic EBV-positive T-cell and NK-cell lymphoproliferative diseases (LPD) of childhood based on classification evolution:new classification,old problems［J］.Am J Surg Pathol,2021,45(5):720-721.
［7］ HONG M,KO YH,YOO KH,et al.EBV-positive T/NK-cell lymphoproliferative disease of childhood［J］.Korean J Pathol,2013,47(2):137-147.
［8］FERESHTEH AMELI,FIROUZEH GHAFOURIAN,NORAIDAH MASIR.Systematic Epstein-Barr virus-positive T-cell lymphoproliferative disease presenting as a persistent fever and cough:a case report［J］.Journal of Medical Case Reports,2014,8:288.
［9］VALENTINA,TABANELLI,CLAUDIO,et al.Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man:A case report and review of the literature［J］.Journal of Medical Case Reports,2011,5:218.
［10］RODRIGUEZ-PINILLA SOCORRO M,BARRIONUEVO CARLOS,GARCIA JUAN,et al.Epstein-Barr virus-positive systemic NK/T-cell lymphomas in children:report of six cases［J］.Histopathology,2011,59(6):1183-1193.
［11］HAN HJ,HONG KT,PARK HJ,et al.Hemophagocytic lymphohistiocytosis as initial presentation of malignancy in pediatric patients:rare but not to be ignored［J］.Children (Basel),2021,8(12):1083.
［12］XIAO HJ,LI J,SONG HM,et al.Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders manifested as gastrointestinal perforations and skin lesions:a case report［J］.Medicine,2016,95(5):e2676.
［13］ WANG Z,KIMURA S,IWASAKI H,et al.Clinicopathological findings of systemic Epstein-Barr virus-positive T-lymphoproliferative diseases in younger and older adults［J］.Diagn Pathol,2021,16(1):48.
［14］CHEN Z,LIU W,ZHAO S.Systemic EBV-positive T-cell lymphoma of childhood mimicking anaplastic large cell lymphoma［J］.Br J Haematol,2019,185(6):1016.
［15］ OHSHIMA K,KIMURA H,YOSHINO T,et al.Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults:overlap with chronic active EBV infection and infantile fulminant EBV T-LPD［J］.Pathol Int,2008,58(4):209-217.
［16］ ZHU Yingying,DUAN Yongtao,SONG Lili,et al.Clinical pathological analysis of systemic EB virus positive T cell lymphoma in children［J］.Journal of Experimental Hematology,2019,27(04):1131-1137.
［17］HUNG GY,YU TY,YEN HJ,et al.Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood presentation with hemophagocytosis［J］.J Pediatr Hematol Oncol,2019,41(4):319-320.
［18］NISHIKUBO M,HIRAMOTO N,YAMASHITA D,et al.Elderly-onset systemic Epstein-Barr virus-positive T-cell lymphoma of childhood［J］.Pathol Int,2022,72(7):376-378.
［19］ JIN Yan,ZHOU Xiaoge,HE Lejian,et al.Clinicopathological observation of systemic EB virus-positive T cell lymphoid tissue proliferative disease in children［J］.Chinese Journal of Pathology,2009,38(009):600-608.
［20］ LV Yang,LI Peifeng,ZHU Jin,et al.Clinicopathological observation of acute childhood systemic Epstein-Barr virus-positive T cell lymphoid tissue proliferative disease［J］.Modern Oncology,2011,19(04):740-745.
［21］EL-MALLAWANY NK,CURRY CV,ALLEN CE.Haemophagocytic lymphohistiocytosis and Epstein-Barr virus:a complex relationship with diverse origins,expression and outcomes［J］.Br J Haematol,2022,196(1):31-44.
［22］SYRYKH C,PERICART S,LAMAISON C,et al.Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases:A review of clinical and pathological features［J］.Cancers (Basel),2021,13(13):3315.
［23］SMITH MC,COHEN DN,GREIG B,et al.The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder［J］.International Journal of Clinical and Experimental Pathology,2014,7(9):5738-5749.
［24］ KAWA K,SAWADA A,SATO M,et al.Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection［J］.Bone Marrow Transplantation,2011,46(1):77-83.
［25］PILLAI V,TALLARICO M,BISHOP MR,et al.Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents［J］.British Journal of Haematology,2016,173(4):573-581.
［26］LEEBORG N,RUSSELL T,FAN G.Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood［J］.Ajsp Reviews & Reports,2012,17(3):120-124.
［27］ PARK S,KIM K,KIM WS,et al.Systemic EBV+T-cell lymphoma in elderly patients:comparison with children and young adult patients［J］.Virchows Arch,2008,453(2):155-163.
［28］TAKADA H,IMADOME KI,SHIBAYAMA H,et al.EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells［J］.PLoS One,2017,12(3):e0174136.
［29］ IMADOME K,SHIRAKATA M,SHIMIZU N,et al.CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation［J］.Proc Natl Acad Sci USA,2003,100(13):7836-7840.
［30］ YOSHIMORI M,IMADOME KI,KOMATSU H,et al.CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals［J］.PLoS One,2014,9(11):e112564.
［31］ IMADOME K,SHIMIZU N,ARAI A,et al.Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival［J］.J Infect Dis,2005,192(8):1340-1348.
［32］ ROTHE M,SARMA V,DIXIT VM,et al.TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40［J］.Science,1995,269(5229):1424-1427.
［33］ CROFT M.The role of TNF superfamily members in T-cell function and diseases［J］.Nat Rev Immunol,2009,9(4):271-285.
［34］ COFFEY AM,LEWIS A,MARCOGLIESE AN,et al.A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood:A single tertiary care pediatric institution experience in North America［J］.Pediatr Blood Cancer,2019,66(8):e27798.
［35］ WANG RC,CHANG ST,HSIEH YC,et al.Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan［J］.Int J Clin Exp Pathol,2014,7(5):2430-2437.
［36］ CHEN G,CHEN L,QIN X,et al.Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome［J］.Int J Clin Exp Pathol,2014,7(10):7110-7113.
［37］ YOSHIDA M,OSUMI T,IMADOME KI,et al.Successful treatment of systemic EBV positive T-cell lymphoma of childhood using the SMILE regimen［J］.Pediatr Hematol Oncol,2018,35(2):121-124.
［38］KIM DO-HOON,KIM MYUNGSHIN,KIM YONGGOO,et al.Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood with good response to steroid therapy［J］.Journal of Pediatric Hematology/Oncology,2017,39(8):E497-E500.
［39］ ONISHI Y,ONODERA K,FUKUHARA N,et al.Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders［J］.Int J Hematol,2022,115(6):873-881.

Memo

Memo:
-
Last Update: 1900-01-01